School of Pharmacy, Nanjing Tech University, 30th South Puzhu Road, Nanjing, 211816, China.
Department of Microbiology and Immunology, Stanford University, Stanford, California 94305, United States.
Mol Pharm. 2022 Jul 4;19(7):2441-2455. doi: 10.1021/acs.molpharmaceut.1c00855. Epub 2022 May 26.
Currently, tumors have become a serious disease threatening human health and life in modern society. Photo-chemo combination therapy is considered to be an important method to improving the efficiency of tumor treatment, especially in the treatment of multi-drug-resistant tumors. However, the application of photo-chemo combination therapy has been limited by the poor water solubility of photosensitizers, low tumor targeting, and high side effects of chemotherapy drugs. In order to solve these problems, a smart nano drug delivery platform FA-PEG-ss-PLL(--Ce6) designed and synthesized by us. The smart nano drug carrier uses folic acid (FA) as the targeting group, polyethylene glycol (PEG) as the hydrophilic end, Ce6-grafted polylysine (PLL(--Ce6)) as the hydrophobic end, and Chlorin e6 (Ce6) as the photosensitizer of photodynamic therapy, and it connects PEG to PLL by a redox-responsive cleavable disulfide linker (-ss-). Finally, the combination of tumor chemotherapy and photodynamic therapy (PDT) is realized by loading with anticancer drug doxorubicin (DOX) to the intelligent carrier. In vitro experiments showed that the drug loading content (DLC%) of DOX@FA-PEG-ss-PLL(--Ce6) nanoparticles (DOX@FPLC NPs) was as high as 14.83%, and the nanoparticles had good serum stability, reduction sensitivity and hemocompatibility. From the cytotoxicity assays in vitro, we found that under 664 nm laser irradiation DOX@FPLC NPs showed stronger toxicity to MCF-7 cells than did DOX, Ce6 + laser, and DOX + Ce6 + laser. Moreover, the antitumor efficiency in vivo and histopathological analysis showed that DOX@FPLC NPs under 664 nm laser irradiation exhibited higher antitumor activity and lower systemic toxicity than single chemotherapy. These results suggested that the FA-PEG-ss-PLL(--Ce6) nano drug delivery platform has considerable potential for the combination of chemotherapy and PDT.
目前,肿瘤已成为现代社会严重威胁人类健康和生命的疾病。光化疗联合治疗被认为是提高肿瘤治疗效率的重要方法,特别是在治疗多药耐药肿瘤方面。然而,光化疗联合治疗的应用受到光敏剂水溶性差、肿瘤靶向性低、化疗药物副作用高等因素的限制。为了解决这些问题,我们设计并合成了一种智能纳米药物递送平台 FA-PEG-ss-PLL(--Ce6)。智能纳米载体以叶酸(FA)为靶向基团,聚乙二醇(PEG)为亲水端,接枝有 Ce6 的聚赖氨酸(PLL(--Ce6))为疏水端,氯代叶绿素 e6(Ce6)为光动力治疗的光敏剂,通过还原响应性可裂解二硫键(-ss-)将 PEG 连接到 PLL 上。最后,通过将抗癌药物阿霉素(DOX)装载到智能载体上,实现了肿瘤化疗和光动力治疗(PDT)的联合。体外实验表明,载药纳米粒 DOX@FA-PEG-ss-PLL(--Ce6)(DOX@FPLC NPs)的载药含量(DLC%)高达 14.83%,且纳米粒具有良好的血清稳定性、还原敏感性和血液相容性。体外细胞毒性实验结果表明,在 664nm 激光照射下,DOX@FPLC NPs 对 MCF-7 细胞的毒性强于 DOX、Ce6+激光和 DOX+Ce6+激光。此外,体内抗肿瘤效率和组织病理学分析表明,在 664nm 激光照射下,DOX@FPLC NPs 比单一化疗具有更高的抗肿瘤活性和更低的全身毒性。这些结果表明,FA-PEG-ss-PLL(--Ce6)纳米药物递送平台在化疗与 PDT 的联合应用中具有很大的潜力。